Does anyone know when EB-001 the shorter acting serotype E botulinum toxin will be available?

EB-001 is a botulinum toxin type E molecule developed by a biotech company called EBS Technologies. It is a shorter-acting version of the botulinum toxin, which means that its effects on muscle activity are thought to last for a shorter duration compared to other botulinum toxin serotypes.
According to the company, EB-001 has a rapid onset of action and a shorter duration of effect, which may make it useful in certain applications where a shorter duration of muscle paralysis is desired. For example, it may be useful in treating certain types of pain or muscle spasticity where long-term paralysis is not necessary.
EB-001 has not yet been approved for use by the US Food and Drug Administration (FDA) or other regulatory agencies, and clinical trials are still ongoing to assess its safety and efficacy. However, early studies have shown promising results, and if approved, it could potentially offer a new option for treating certain conditions that are currently treated with other botulinum toxin serotypes.